Form 4 for CBIO CRESCENT BIOPHARMA, INC.
Accepted 2024-06-20 00:00:00 ET · period of report 2024-06-18 · accession 0001415889-24-017623 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-06-20 | 2024-06-18 | CBIO | Hahn Brian M. | CFO, SVP Fin | P - Purchase | $0.25 | +17.5K | 70.6K | +33% | +$4,375 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-06-18 | P | A | 17,500 | $0.25 | 70,643 | D | — | — | (F1) The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.2453 to $0.2478 per share, with a weighted average purchase price of $0.2477 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. |